The stock has been in a weak trend for more than a year.
Let's review the charts and indicators.
I was trying really hard to like CVS today, but I do not love this balance sheet.
The healthcare enterprise reports earnings Tuesday before the market opens.
Both names should see growth in 2023 and they're reasonably valued.
Let's check on the charts and indicators of the cutting-edge CRISPR editing company.
What are chart patterns indicating?
Let's check the charts and indicators.
Six investment experts look beyond the traditional pharmaceutical names to highlight their favorite sector plays for the coming year.
Two in five Americans are obese. Treatments that target obesity directly could be the next blockbuster pharma category.